Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.
about
Vaccine adjuvants as potential cancer immunotherapeuticsSaponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formationThe mouse Mageb18 gene encodes a ubiquitously expressed type I MAGE protein and regulates cell proliferation and apoptosis in melanoma B16-F0 cellsA randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses.Trial Watch: Toll-like receptor agonists in oncological indications.B cell TLRs and induction of immunoglobulin class-switch DNA recombination.TLR-based immune adjuvants.Adjuvant therapy: melanomaVaccine Potentiation by Combination AdjuvantsA Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing TumorsTrial watch: FDA-approved Toll-like receptor agonists for cancer therapy.Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on primingCytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunitCancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E.Toll-like receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes.Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).Optimized subunit vaccine protects against experimental leishmaniasis.Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer.Cancer-germline antigen vaccines and epigenetic enhancers: future strategies for cancer treatment.MAGE A3 antigen-specific cancer immunotherapeutic.Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.MAGE-A3: an immunogenic target used in clinical practice.TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.Immunotherapy of head and neck cancer: current and future considerations.Heterogeneous expression of melanoma antigen (hMAGE) mRNA in mesenchymal neoplasia.Genetically modified T lymphocytes: more than just direct effectors.Prognostic value of melanoma-associated antigen A9 in renal cell carcinoma.Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.Immune checkpoint inhibitors in melanomaAdjuvant therapy for melanoma
P2860
Q26752522-2E3CECC8-C4D6-4E8C-AC50-1D5D798F048DQ28393754-B6FEB942-9F05-4099-BC5D-7C9AB54BAA84Q28586544-6AAC3A77-BD2B-4004-96C5-1631D1FD7E7CQ30278070-A40BD3E5-0502-446C-BC32-148A3D5712E2Q30299957-E2E7934D-2C04-4D1B-82AF-881CA5B8D4C9Q33617905-C262F9D1-CCFE-4A4B-899C-B2EEC7001045Q33878578-9A10AFA6-B2A0-49E1-B0BE-EF77C68E6596Q33893517-E3E7DC9E-097B-4682-AEBC-C6F9F7BB999DQ34400322-71689A89-FD6E-47AD-A742-FD9AAD8A031AQ35636225-AAC4D21E-82A0-430A-BA0D-C0AE892B0DD1Q35826767-639D0B66-12B2-4927-8B3D-302EBE77F65AQ36322371-D122F122-C242-4DDE-9C1B-5209C28E7989Q36373370-2518FE3F-A023-4F50-88D0-CA1C5FBE4112Q36446446-A5D1F87E-F707-46E4-9B83-CDF1FB5AED5BQ36544143-6D52BA2A-65CD-4C24-ACDC-1114B50006DBQ36561664-81C11E92-9966-4C05-A212-13261553ECC4Q37137098-95677C8A-92CA-46CE-9A23-0796935B2A61Q37170344-C467C47E-70B2-4631-BAB9-22CBC93EF366Q37281267-17B247C3-E584-4310-A31E-2BD800F93A84Q37439440-FE329084-B3DF-4916-A372-F3CD428E599BQ37619114-82E98C1C-8005-49D9-8BDF-7F5E208E5CE4Q37737327-2729EC5F-DBC2-43BE-B6BF-940E81B6CD86Q37773275-9458BA66-A3ED-4755-9255-EE0F13687E93Q37867102-CB785F20-3EDF-4381-A139-DCE7A3179C79Q38534721-34F16598-83AD-4A5B-BD7B-167F8D4BFCE6Q39383424-A8137407-09E3-414F-93D5-3CC17FB0C114Q39955461-25670420-9E3F-4704-9CA7-68A088816C86Q40267997-2DB6C213-2440-4EF0-8F4C-B2E9C8797729Q43536357-623900D5-74E3-40EC-B8F0-EC4D12C0606FQ44312375-90DC87F2-E3E7-4DEA-B104-F2159ACE127DQ55136811-4358E280-D14C-498A-8EF2-C38036558BAEQ56895914-88A36504-82F1-4FDE-A158-743D3FC473D2Q56898212-CAA3504F-3FA6-4EF4-B9AB-BCDEC23000D5
P2860
Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Immunologic analysis of a phas ...... s with MAGE-3-positive tumors.
@en
Immunologic analysis of a phas ...... s with MAGE-3-positive tumors.
@nl
type
label
Immunologic analysis of a phas ...... s with MAGE-3-positive tumors.
@en
Immunologic analysis of a phas ...... s with MAGE-3-positive tumors.
@nl
prefLabel
Immunologic analysis of a phas ...... s with MAGE-3-positive tumors.
@en
Immunologic analysis of a phas ...... s with MAGE-3-positive tumors.
@nl
P2093
P1476
Immunologic analysis of a phas ...... s with MAGE-3-positive tumors.
@en
P2093
Cedrik M Britten
Christine Dantinne
Claudine Bruck
Cor H J Lamers
Dirk Gheysen
Gerrit Stoter
Marcel Delire
Marie Marchand
Maryse Guéguen
Noreddine Amrani
P304
P356
10.1097/00002371-200403000-00006
P577
2004-03-01T00:00:00Z